ClinicalTrials.gg

Program

teplizumab

Also written as “Teplizumab”, “teplizumab 1 mg/mL” and “Teplizumab Herold Regimen”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Psoriasis, led by 3 companies.

Furthest: phase 4, since Feb 13, 20239 company-led studies, 2 open or runningNext primary completion: Mar 6, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi52 open or runningphase 4since Feb 13, 2023Mar 13, 2019Mar 6, 2028phase 2 · NCT06791291
MacroGenics30 open or runningphase 3since Oct 7, 2006Oct 7, 2006none ahead
Precigen Actobio T1D10 open or runningphase 2since Nov 8, 2018Nov 8, 2018none ahead

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2006First study: phase 3 study in Diabetes Mellitus, Type 1New to MacroGenicsMacroGenics · NCT00385697 · 554 enrolled · United States, Canada, Czechia and more
  2. Jun 12, 2009Phase 3 study in Diabetes Mellitus, Type 1MacroGenics · NCT00920582 · 254 enrolled · United States, Belgium, Czechia and more
  3. Aug 4, 2009Phase 2 study in PsoriasisMacroGenics · NCT00954915 · 1 enrolled · United States
  4. Nov 8, 2018Precigen Actobio T1D's first study: phase 2 study in Diabetes type1New to Precigen Actobio T1DPrecigen Actobio T1D · NCT03751007 · 45 enrolled · United States, Belgium
  5. Mar 13, 2019Sanofi's first study: phase 3 study in Diabetes Mellitus, Type 1New to SanofiSanofi · NCT03875729 · 328 enrolled · United States, Belgium, Canada and more
  6. Feb 10, 2020Phase 2 study in Diabetes Mellitus, Type 1Sanofi · NCT04270942 · 6 enrolled · United States
  7. Feb 13, 2023Phase 4 study in Diabetes Mellitus, Type 1Sanofi · NCT05757713 · 23 enrolled · United States
  8. Jan 20, 2025Phase 2 study in Diabetes Mellitus, Type 1Sanofi · NCT06791291 · 5 enrolled · Japan
  9. Jul 20, 2025Phase 3 study in Diabetes Mellitus, Type 1Sanofi · NCT07088068 · 723 planned · United States, Argentina, Australia and more

Ahead

  1. Mar 6, 2028Primary completion: phase 2 study in Diabetes Mellitus, Type 1Sanofi · NCT06791291
  2. Jun 6, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 1Sanofi · NCT07088068

TargetBeta

CD3E →read by rule
“T-cell surface glycoprotein CD3 epsilon chain other”ChEMBL 37, by rule

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07088068Diabetes Mellitus, Type 1 · United States, Argentina, Australia and more3RecruitingSanofiJun 6, 2028723
NCT06791291Diabetes Mellitus, Type 1 · Japan2Active, not recruitingSanofiMar 6, 20285
NCT05757713Diabetes Mellitus, Type 1 · United States4CompletedSanofiAug 28, 202623
NCT04270942Diabetes Mellitus, Type 1 · United States2CompletedSanofiJan 22, 20246
NCT03875729Diabetes Mellitus, Type 1 · United States, Belgium, Canada and more3CompletedSanofiMay 1, 2023328
NCT03751007Diabetes type1 · United States, Belgium2CompletedPrecigen Actobio T1DOct 13, 202145
NCT00954915Psoriasis · United States2TerminatedMacroGenicsJul 20101
NCT00920582Diabetes Mellitus, Type 1 · United States, Belgium, Czechia and more3TerminatedMacroGenicsApr 2012254
NCT00385697Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more3CompletedMacroGenicsJun 2010554

How it is read

Names in the registry

  • “Teplizumab”, 4 entries
  • “teplizumab”, 3 entries
  • “teplizumab 1 mg/mL”, 1 entry
  • “Teplizumab Herold Regimen”, 1 entry
  • “Teplizumab 33.3% Herold Regimen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.